Home
/
Rein Therapeutics, Inc.
/
Financials
/
Quarterly
Rein Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Rein Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 9, 2018
Q3
2017
Sep 30, 2017
$0
Nov 9, 2017
Q2
2017
Jun 30, 2017
$0
Aug 10, 2017
Q1
2018
Mar 31, 2017
$0
May 9, 2018
Q3
2017
Sep 30, 2016
$0
Nov 9, 2017
Q2
2017
Jun 30, 2016
$0
Aug 10, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 14, 2025
Q2
2025
Jun 30, 2025
$0
Aug 14, 2025
Q1
2025
Mar 31, 2025
$0
May 15, 2025
Q3
2025
Sep 30, 2024
$0
Nov 14, 2025
Q2
2025
Jun 30, 2024
$0
Aug 14, 2025
Q1
2025
Mar 31, 2024
$0
May 15, 2025
Q3
2024
Sep 30, 2023
$0
Nov 14, 2024
Q2
2024
Jun 30, 2023
$0
Aug 14, 2024
Q1
2024
Mar 31, 2023
$0
May 15, 2024
Q3
2023
Sep 30, 2022
$0
Oct 13, 2023
Q2
2023
Jun 30, 2022
$0
Aug 11, 2023
Q1
2023
Mar 31, 2022
$0
May 8, 2023
Q3
2022
Sep 30, 2021
$0
Nov 1, 2022
Q2
2022
Jun 30, 2021
$0
Aug 15, 2022
Q1
2022
Mar 31, 2021
$0
May 5, 2022
Q3
2021
Sep 30, 2020
$0
Nov 12, 2021
Q2
2021
Jun 30, 2020
$0
Aug 11, 2021
Q1
2021
Mar 31, 2020
$0
May 11, 2021
Q3
2020
Sep 30, 2019
$0
Nov 12, 2020
Q2
2020
Jun 30, 2019
$0
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.58M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($6.82M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($6.82M)
Nov 14, 2025
Q1
2025
Mar 31, 2025
($5.50M)
May 15, 2025
Q3
2025
Mar 31, 2025
($5.50M)
Nov 14, 2025
Q2
2025
Mar 31, 2025
($5.50M)
Aug 14, 2025
Q3
2025
Sep 30, 2024
($5.85M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($8.94M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($8.94M)
Nov 14, 2025
Q3
2025
Mar 31, 2024
($7.11M)
Nov 14, 2025
Q2
2025
Mar 31, 2024
($7.11M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($7.11M)
May 15, 2025
Q3
2024
Sep 30, 2023
($1.83M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.79M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($1.79M)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($4.78M)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($4.78M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($4.78M)
May 15, 2024
Q3
2023
Sep 30, 2022
($6.37M)
Oct 13, 2023
Q3
2023
Jun 30, 2022
($7.99M)
Oct 13, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.49M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($6.87M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($5.61M)
May 15, 2025
Q3
2025
Sep 30, 2024
($6.07M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($9.04M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($7.21M)
May 15, 2025
Q3
2024
Sep 30, 2023
($1.98M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.99M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.01M)
May 15, 2024
Q3
2023
Sep 30, 2022
($6.48M)
Oct 13, 2023
Q2
2023
Jun 30, 2022
($8.04M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($8.42M)
May 8, 2023
Q3
2022
Sep 30, 2021
($6.79M)
Nov 1, 2022
Q2
2022
Jun 30, 2021
($6.01M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($6.99M)
May 5, 2022
Q3
2021
Sep 30, 2020
($5.03M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($4.40M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
($6.88M)
May 11, 2021
Q3
2020
Sep 30, 2019
($7.92M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($7.38M)
Aug 5, 2020